FDA Approved: MAYZENT — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA granted approval of a supplemental application for MAYZENT (siponimod) from Novartis Pharmaceuticals Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Multiple Sclerosis
• Relapsing Forms of Multiple Sclerosis

Drugs mentioned

• MAYZENT (siponimod)

Snippet

SUPPL AP for MAYZENT (SIPONIMOD)